Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...

The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the ...

For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, treatment options after chemotherapy fails have been essentially nonexistent ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Daraxonrasib is the first investigational agent in a novel class of RAS (ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

An international study co-led by UCLA found that an investigational targeted therapy significantly extended survival for pancreatic cancer patients, researchers said Sunday. The study found that ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.